 |
Grants Received: Dr. Kevin Kjernisted
| |
NRC Grant (2003) SPECT study – Dopamine Receptors in Social Anxiety Disorder and OCD ($25,000). Co-investigator
|
|
| |
Glaxo SmithKline(2001): Development and Validation of Worry-3 Screening Tool for Generalized Anxiety Disorder ($30,000). Principal Investigator
|
|
| |
Organon Canada (2000): Open Trial of Andriol in Androgen Deficiency to Assess Quality of Life ($40,000). Principal Investigator
|
|
| |
McMaster University (1999 to Present): Placebo Controlled Trial with Nefazodone for Social Phobia ($100,000). Principal Investigator
|
|
| |
NIMH (USA) (1993 to Present): Kjernisted, K.D. Obsessive Compulsive Disorder: Combined Clomipramine and CBT Versus Either Treatment Alone, Leibowitz, Foa, K.D. Kjernisted ($20,000).
|
|
| |
Bristol Myers Squibb (1998) - Open Label Trial with Nefazodone for Hypochondriasis ($12,000). Principal Investigator
|
|
| |
Medical Research Council of Canada: WALKER, J.R., Cox, B.J., Frankel, S. Evaluating Two Cognitive Behavioural Self-Help Approaches for Social Phobia ($65,000), K.D. Kjernisted, Consultant Psychiatrist. |
|
« Back to Research |
|
|
|
